Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 801–900 of 1,020
Klaassen, R., Steins, A., Gurney‐Champion, O. J., Bijlsma, M. F., van Tienhoven, G., Engelbrecht, M. R. W., van Eijck, C. H. J., Suker, M., Wilmink, J. W., Besselink, M. G., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12688 · Cited by 47
“Variation in these three biological characteristics of PDAC – desmoplasia, hypovascularization, and hypoxia – have been related to differences in treatment outcome (Bailey et al., 2016; Puleo et al., 2018).”
BackgroundSingh, K., Pruski, M. A., Bland, R., Younes, M., Guha, S., Thosani, N. C., Maitra, A., Cash, B. D., McAllister, F. M., Logsdon, C. D., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00490-5 · Cited by 46
Self-citationAbd-El-Halim, Y. M., Kaoutari, A. E., Silvy, F., Rubis, M., Bigonnet, M., Roques, J., Cros, J. F., Nicolle, R., Iovanna, J., Dusetti, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103541 · Cited by 52
“The Australian cohort of International Cancer Genome Consortium (ICGC) was used as external validation cohort for the glyco-signature [10].”
MethodDelivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 46
Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma
Chen, X., Mo, S., Zhang, Y., Ma, H., Lu, Z., Yu, S., & Chen, J. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.260 · Cited by 52
“Genomic analysis has shown that DNA repair is one of the core signalling pathways, and some of the key molecules in the DNA damage repair (DDR) pathways, including BRCA1, BRCA2, PALB2, and p53, play an important role in the development of PDAC [21,22].”
BackgroundJakobsdottir, G. M., Brewer, D. S., Cooper, C., Green, C., & Wedge, D. C. (2022) · BMC Biology · doi:10.1186/s12915-022-01316-0 · Cited by 47
Schaal, J. L., Bhattacharyya, J., Brownstein, J. M., Strickland, K. C., Kelly, G., Saha, S., Milligan, J. J., Banskota, S., Li, X., Liu, W., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00949-4 · Cited by 46
Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer
Veghini, L., Pasini, D., Fang, R., Delfino, P., Filippini, D., Neander, C., Vicentini, C., Fiorini, E., Lupo, F., D’Agosto, S. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54975-8 · Cited by 53
“Next, we applied a multiplex immuno fl uorescence (mIF) to 15 human PDAC tissues where neoplastic cells were classi fi ed as either basal-like or classical with well-established tissue markers 15,34 – 37 (Fig.1b).”
InfluentialSelf-citationSolinas, C., Pusole, G., Demurtas, L., Puzzoni, M., Mascia, R., Morgan, G., Giampieri, R., & Scartozzi, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.016 · Cited by 48
Mind the (sr)GAP – roles of Slit–Robo GAPs in neurons, brains and beyond
Lucas, B., & Hardin, J. D. (2017) · Journal of Cell Science · doi:10.1242/jcs.207456 · Cited by 43
“Like the Slit–Robo system, which has been implicated in gastric (Huang et al., 2015) and pancreatic cancer (Bailey et al., 2016; Biankin et al., 2012), srGAPs have also been connected to cancer.”
BackgroundTesfaye, A. A., Kamgar, M., Azmi, A. S., & Philip, P. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417844 · Cited by 49
Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F. R., Cooke, S., Marshall, J., Beraldi, D., Knight, S. R., Upstill‐Goddard, R., Dickson, E. J., et al. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.04.06 · Cited by 43
Self-citationT-Cell Immunity in Pancreatic Cancer
Ajina, R., & Weiner, L. M. (2020) · Pancreas · doi:10.1097/mpa.0000000000001621 · Cited by 50
scLink: Inferring Sparse Gene Co-Expression Networks from Single-Cell Expression Data
Li, W. V., & Li, Y. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.11.006 · Cited by 47
“For instance, transcriptional dysregulation revealed by disease-associated gene interactions has been reported in various diseases including cancer [4], neurological disorders [5], and psychiatric disorders [6], leading to functional insights of transcriptome organization in disease progression.”
Simon, T., Riemer, P., Detjen, K. M., Domenico, A. D., Bormann, F., Menne, A., Khouja, S., Monjé, N., Childs, L. H., Lenze, D., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01018-w · Cited by 49
“In addition, 167 PDAC 450K methylation data was also obtained from GSE49149 [49].”
MethodMastracci, L., Grillo, F., Parente, P., Gullo, I., Campora, M., Angerilli, V., Rossi, C., Sacramento, M. L., Pennelli, G., Vanoli, A., et al. (2022) · Pathologica · doi:10.32074/1591-951x-803 · Cited by 51
MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
Modica, C., Tortarolo, D., Comoglio, P. M., Basilico, C., & Vigna, E. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123920 · Cited by 46
“About 94% of these cancers develop from the exocrine tissues and are classified in four subtypes: ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary-mucinous neoplasm, and mucinous cystic neoplasm [88].”
BackgroundAssessment of spatial transcriptomics for oncology discovery
Lyubetskaya, A., Rabe, B. A., Fisher, A., Lewin, A. C., Neuhaus, I., Brett, C., Brett, T., Pereira, E. R., Golhar, R., Kebede, S., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100340 · Cited by 49
“To identify tumor regions using gene signatures, we compiled PDAC bulk RNA sequencing (RNA-seq) signatures from prior molecular subtyping efforts by Collison et al.,87 Moffit et al.,44 and Bailey et al.30 and calculated tumor signature scores for every capture spot (STAR Methods).”
BackgroundClinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer
Singh, H., Xiu, J., Kapner, K. S., Yuan, C., Narayan, R. R., Oberley, M. J., Farrell, A. P., Surana, R., Huffman, B. M., Perez, K. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1164 · Cited by 56
Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models
Schmidt, K. M., Hellerbrand, C., Ruemmele, P., Michalski, C. W., Kong, B., Kroemer, A., Hackl, C., Schlitt, H. J., Geissler, E. K., & Lang, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.15524 · Cited by 46
“In addition, the squamous tumor subtype was enriched for activated integrin and EGF signaling, both known to be influenced by mTORC2/RICTOR [29, 49, 50].”
BackgroundRe-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked
Evan, G. I., Hah, N., Littlewood, T. D., Sodir, N. M., Campos, T., Downes, M., & Evans, R. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3275 · Cited by 45
Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Borazanci, E. H., Dang, C. V., Robey, R. W., Bates, S. E., Chabot, J. A., & Hoff, D. D. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2070 · Cited by 50
“The other subtypes include the pancreatic progenitor subtype involving several transcription factors important for diabetes, fatty acid oxidation, steroid hormone biosynthesis, mucin modification, and drug metabolism; the ADEX subtype representing a more terminally differentiated phenotype; and the immunogenic subtype…”
BackgroundScreening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery
D’Agostino, V., Sighel, D., Zucal, C., Bonomo, I., Micaelli, M., Lolli, G., Provenzani, A., Quattrone, A., & Adami, V. (2019) · SLAS DISCOVERY · doi:10.1177/2472555218818065 · Cited by 46
Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble?
Moutinho-Ribeiro, P., Macedo, G., & Melo, S. A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00779 · Cited by 46
Low P4HA2 and high PRTN3 expression predicts poor survival in patients with pancreatic cancer
Hu, D., Ansari, D., Zhou, Q., Sasor, A., Hilmersson, K. S., & Andersson, R. E. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1574360 · Cited by 45
Dehghannasiri, R., Freeman, D. E., Jordanski, M., Hsieh, G. L., Damljanovic, A., Lehnert, E. M., & Salzman, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900391116 · Cited by 47
“As one of many examples, a recent study of more than 400 pancreatic cancers found no recurrent gene fusions, raising the question of whether this is due to high FN rates or whether this means that fusions are not drivers in the disease (18).”
BackgroundPrecision medicine in pancreatic cancer: treating every patient as an exception
Herbst, B. T., & Zheng, L. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30175-x · Cited by 47
Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
Franck, C., Müller, C., Rosania, R., Croner, R. S., Pech, M., & Venerito, M. (2020) · Cancers · doi:10.3390/cancers12071955 · Cited by 45
“, which is based on a whole-genome and deep-exome sequencing, with gene copy number analysis of 456 PDAC samples [10].”
BackgroundJentzsch, V., Davis, J., & Djamgoz, M. B. A. (2020) · Cancers · doi:10.3390/cancers12113096 · Cited by 46
Yu, Y., Yang, G., Huang, H., Fu, Z., Cao, Z., Zheng, L., You, L., & Zhang, T. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01787-5 · Cited by 49
Ho, K., Huang, T.-W., Shih, C.-M., Lee, Y.-T., Liu, A.-J., Chen, P., & Chen, K. (2021) · BMC Medicine · doi:10.1186/s12916-021-01925-6 · Cited by 43
“For cluster 1 patients, all their histological types belonged to neuroendocrine, which was excluded in the study that defined these molecular subtypes [20].”
BackgroundKDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway
Yi, Z., Wei, S., Jin, L., Jeyarajan, S., Yang, J., Gu, Y., Kim, H. S., Schechter, S., Lu, S., Paulsen, M. T., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.09.014 · Cited by 41
Konings, I. C. A. W., Harinck, F., Poley, J.-W., Aalfs, C. M., van Rens, A., Krak, N. C., Wagner, A., Nio, C. Y., Sijmons, R. H., van Dullemen, H. M., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000725 · Cited by 41
“With regard to the significantly higher prevalence of cystic lesions in the group of FPC individuals, it is tempting to speculate that this might be indicative of a difference in pathophysiology or in molecular subtypes of PDAC 28 between the 2 high-risk groups.”
Shinkawa, T., Ohuchida, K., Mochida, Y., Sakihama, K., Iwamoto, C., Abe, T., Ideno, N., Mizuuchi, Y., Shindo, K., Ikenaga, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02301-9 · Cited by 41
Pihlak, R., Weaver, J. M. J., Valle, J. W., & McNamara, M. G. (2018) · Cancers · doi:10.3390/cancers10010017 · Cited by 43
“data [24] also showed upregulation of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1, hypothesising that this subgroup could be treated with novel immunotherapies.”
BackgroundInfluentialIdentifying Molecular Biomarkers for Diseases With Machine Learning Based on Integrative Omics
Shi, K., Lin, W. J., & Zhao, X. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.2986387 · Cited by 49
“[78] identified molecular subtypes of pancreatic cancer with genomics data based on top variable genes as input of NMF, and Bramsen et al .”
Deep Subspace Mutual Learning for cancer subtypes prediction
Yang, B., Xin, T., Pang, S., Wang, M., & Wang, Y.-J. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab625 · Cited by 43
Topham, J. T., Tsang, E. S., Karasinska, J. M., Metcalfe, A. L., Ali, H., Kalloger, S. E., Csizmók, V., Williamson, L., Titmuss, E., Nielsen, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33718-7 · Cited by 45
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Erice, O., Narayanan, S., Feliu, I., Entrialgo‐Cadierno, R., Malinova, A., Vicentini, C., Guruceaga, E., Delfino, P., Trajkovic‐Arsic, M., Moreno, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0794 · Cited by 42
Self-citationStorrs, E. P., Chati, P., Usmani, A., Sloan, I. H., Krasnick, B. A., Babbra, R. K., Harris, P. K. W., Sachs, C. M., Qaium, F., Chatterjee, D., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00455-z · Cited by 53
“Overall, the makeup of PE1 and PE6 corroborates known biology, with immune fraction being associated with increased survival 31 and the relatively improved prognosis of the classical PDAC subtype compared to basal-like 3,5,6 .”
BackgroundMethodInfluentialPerioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Clinical Trial
Cecchini, M., Salem, R. R., Robert, M. E., Czerniak, S., Bláha, O., Zelterman, D. A., Rajaei, M., Townsend, J. P., Cai, G., Chowdhury, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1575 · Cited by 53
Link, J. M., Eng, J. R., Pelz, C., Hawthorne, K., Worth, P. J., Sivagnanam, S., Keith, D., Owen, S., Langer, E. M., Grossblatt-Wait, A., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00881-3 · Cited by 49
“Previous efforts to divide PDAC tumors into subtypes used unbiased approaches to describe mutually exclusive subsets 9,11,13,14,47,48 .”
InfluentialCellNEST reveals cell–cell relay networks using attention mechanisms on spatial transcriptomics
Zohora, F. T., Paliwal, D., Figueroa, E. F., Li, J., Gao, T., Notta, F., & Schwartz, G. W. (2025) · Nature Methods · doi:10.1038/s41592-025-02721-3 · Cited by 58
Mannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 143
“85,90 The basal - like subtype is characterized by a more aggressive phenotype, poorer prognosis, and resistance to standard therapies.”
Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling
Humphrey, E. S., Su, S., Nagrial, A. M., Hochgräfe, F., Pajic, M., Lehrbach, G. M., Parton, R. G., Yap, A. S., Horvath, L. G., Chang, D. K.-F., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058313 · Cited by 43
Self-citationJahny, E., Yang, H., Liu, B., Jahnke, B., Lademann, F., Knösel, T., Rümmele, P., Grützmann, R., Aust, D. E., Pilarsky, C. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170390 · Cited by 42
Self-citationStromal SPOCK 1 supports invasive pancreatic cancer growth
Veenstra, V. L., Damhofer, H., Waasdorp, C., Steins, A., Kocher, H. M., Medema, J. P., van Laarhoven, H. W. M., & Bijlsma, M. F. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12073 · Cited by 42
“, 2013); GSE36924, P erez-Mancera/Wu (Bailey et al., 2016; Perez-Mancera et al., 2012).”
Complex HuR function in pancreatic cancer cells
Brody, J. R., & Dixon, D. A. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1469 · Cited by 43
Ductal vs. acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma
Xu, Y., Liu, J., NIPPER, M. J., & Wang, P. (2019) · Annals of Pancreatic Cancer · doi:10.21037/apc.2019.06.03 · Cited by 45
“Recent genomic analysis of PDAC samples identified gene expression patterns which defined several PDAC subtypes that correlate with histopathological characteristics (5-7).”
BackgroundPan‐cancer RNA‐seq data stratifies tumours by some hallmarks of cancer
Frost, F. G., Cherukuri, P. F., Milanovich, S. J., & Boerkoel, C. F. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14746 · Cited by 50
Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis
Ogawa, K., Lin, Q., Li, L., Bai, X., Chen, X., Chen, H., Kong, R., Wang, Y., Zhu, H., He, F., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.039 · Cited by 41
“ASPH activates Notch1 cascade [35,36] in the primary PDAC tumor, upregulates downstream target genes (e.”
BackgroundSelf-citationEndocrine and Metabolic Insights from Pancreatic Surgery
Mezza, T., CEFALO, C. M. A., Cinti, F., Quero, G., Pontecorvi, A., Alfieri, S., Holst, J. J., & Giaccari, A. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.07.003 · Cited by 46
“However, comparing differently expressed genes with the transcriptomic signature of pancreatic cancer, no evidence was found for contamination of samples from surgery with cancer cells [83], and, in view of rapid amelioration after pancreas head tumor removal, Ehehalt et al.”
Oweida, A. J., Mueller, A. C., Piper, M., Milner, D. C., Court, B. V., Bhatia, S., Phan, A. V., Bickett, T. E., Jordan, K. R., Proia, T. A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02701-w · Cited by 48
Repurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 46
Striefler, J. K., Riess, H. B., Lohneis, P., Bischoff, S., Kurreck, A., Modest, D. P., Bahra, M., Oettle, H., Sinn, M., Bläker, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670396 · Cited by 42
“586 N− 28 (21) 6 (26) N+ 107 (79) 17 (74) Grading, (%) .”
Inflammation and Myeloid Cells in Cancer Progression and Metastasis
Deng, J., & Fleming, J. B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.759691 · Cited by 47
Localized Pancreatic Cancer: Multidisciplinary Management
Coveler, A. L., Herman, J. M., Simeone, D. M., & Chiorean, E. G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160827 · Cited by 42
Canonical Hedgehog Pathway and Noncanonical GLI Transcription Factor Activation in Cancer
Suchors, C., & Kim, J. (2022) · Cells · doi:10.3390/cells11162523 · Cited by 50
“Mutations in Hh pathway components are rare [146,147] suggesting that intact canonical ligand-dependent pathway was active in pancreas cancers.”
BackgroundLatest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer
Mouratidis, P., & ter Haar, G. (2022) · Cancers · doi:10.3390/cancers14030638 · Cited by 46
Shukla, H. D. (2017) · Proteomes · doi:10.3390/proteomes5040028 · Cited by 43
“In a similar study, a genomic analysis of 456 PDAC samples identified 32 genes which impacted or altered 10 signaling pathways, and a further expression analysis of these samples identified four cancer subtypes which could help in designing an appropriate therapeutic options [52].”
ResultGenomic testing for pancreatic cancer in clinical practice as real-world evidence
Hayashi, H., Tanishima, S., Fujii, K., Mori, R., Okamura, Y., Yanagita, E., Matsuoka, R., Amano, T., Kinoshita, I., Komatsu, Y., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.07.006 · Cited by 43
Parente, P., Parcesepe, P., Covelli, C., Olivieri, N., Remo, A., Pancione, M., Latiano, T. P., Graziano, P., Maiello, E., & Giordano, G. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/7530619 · Cited by 40
“Interestingly, the immunogenic subtype is characterized by a predominant B- and T-cell (CD8+, Treg) infiltrate as well as cytotoxic T lymphocyte antigen-4 (CTLA4) and PD-1 upregulation [70].”
BackgroundIdeno, N., Yamaguchi, H., Okumura, T., Huang, J. H., Brun, M. J., Ho, M. L., Suh, J., Gupta, S., Maitra, A., & Ghosh, B. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0171-z · Cited by 42
Self-citationRET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas
Chou, A. S. Y., Brown, I., Kumarasinghe, P. M., Perren, A. A., Riley, D., Kim, Y., Pajic, M., Steinmann, A. M., Rathi, V., Jamieson, N. B., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0373-y · Cited by 40
Self-citationKumarasamy, V. M., Ruiz, A., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2019) · Oncogene · doi:10.1038/s41388-019-1102-1 · Cited by 41
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Valencia, K., Erice, O., Kostyrko, K., Hausmann, S., Guruceaga, E., Tathireddy, A., Flores, N. M., Sayles, L. C., Lee, A. G., Fragoso, R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129012 · Cited by 46
“This approach likely identifies different miRNAs compared with overexpression of KRAS, which is known to lead to a distinct outcome in pri-human lung cancer data set (The Cancer Genome Atlas [TCGA]; https://www.cancer.gov/about-nci/organization/ccg/research/ structural-genomics/tcga) and pancreatic cancer data set (In…”
Kalisvaart, M., Broadhurst, D., Marcon, F., Pandé, R., Schlegel, A. A., Sutcliffe, R. P., Marudanayagam, R., Mirza, D. F., Chatzizacharias, N. A., Abradelo, M., et al. (2020) · HPB · doi:10.1016/j.hpb.2020.01.005 · Cited by 40
“However, these systemic therapies come with a risk of toxicity and due to the large variety in genetics of pancreatic malignancies, they do not target all tumours.(29) As a result, the majority of the patients still develop recurrent disease.”
BackgroundNelson, S. R., Zhang, C., Roche, S., O’Neill, F., Swan, N., Luo, Y., Larkin, A., Crown, J., & Walsh, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-59368-7 · Cited by 38
Yang, B., Zhang, B., Cao, Z., Xu, X., Huo, Z., Zhang, P., Xiang, S., Zhao, Z., Lv, C., Meng, M., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0514-3 · Cited by 44
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Henze, J., Tacke, F., Hardt, O., Alves, F., & Rawashdeh, W. A. (2020) · Cancers · doi:10.3390/cancers12061389 · Cited by 46
“[15] defined for example four subtypes of PDAC, based on genomic analysis correlating with histopathological characteristics.”
BackgroundWeng, W., Zhang, Z., Huang, W., Xu, X., Wu, B., Ye, T., Shan, Y., Shi, K., & Lin, Z. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01243-6 · Cited by 44
“, the gene network of the four subtypes of pancreatic tumors all involved in TGF-β signaling pathway, among which the squamous subtype with significant P53 gene mutation has the worst prognosis [25].”
Usón, P. L. S., Samadder, N. J., Riegert‐Johnson, D. L., Boardman, L., Borad, M. J., Ahn, D. H., Sonbol, M. B., Faigel, D. O., Fukami, N., Pannala, R., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000414 · Cited by 46
Geleta, B., Shehadeh-Tout, F., Lim, S. C., Sahni, S., Jansson, P. J., Apte, M. V., Richardson, D. R., & Kovačević, Ž. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101608 · Cited by 40
A p300/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models
Zhong, Z., Harmston, N., Wood, K. C., Madan, B., & Virshup, D. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156305 · Cited by 44
“The GATA6 genomic locus is hypermethylated in the GATA6-low basal-like pancreatic tumors (7), although this may be a late event that reinforces rather than establishes GATA6 silencing (81–83).”
BackgroundToward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics
Yu, H. S., Gao, C., Lupyan, D., Wu, Y., Kimura, T., Wu, C., Jacobson, L., Harder, E., Abel, R., & Wang, L. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00268 · Cited by 39
Anglin, J., Zavareh, R. B., Sander, P. N., Haldar, D., Mullarky, E., Cantley, L. C., Kimmelman, A. C., Lyssiotis, C. A., & Lairson, L. L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.061 · Cited by 39
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 44
Katz, M. H. G., Petroni, G. R., Bauer, T. W., Reilley, M. J., Wolpin, B. M., Stucky, C., Bekaii‐Saab, T., Elias, R., Merchant, N. B., Costa, A. D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007586 · Cited by 41
Sha, H., Tong, F., Ni, J., Sun, Y., Zhu, Y., Qi, L., Li, X., Li, W., Yang, Y., Gu, Q., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01857-6 · Cited by 40
“14,15 Clinical, genomic and transcriptomic analyses were executed to explore biomarkers via pretreatment specimens of ef fi cacy response and survival for PAAG in our study.”
Fraunhoffer, N. A., Hammel, P. R., Conroy, T., Nicolle, R., Bachet, J., Harlé, A., Rebours, V., Turpin, A., Abdelghani, M. B., Mitry, E., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.010 · Cited by 51
Wang, H., Zheng, H., Wang, J., Wang, C., & Wu, F. (2016) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2016.2556640 · Cited by 39
Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.001 · Cited by 41
Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials
Jiang, M., Dai, J., Gu, D.-N., Huang, Q., & Tian, L. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.08.002 · Cited by 42
TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma
Lin, R., Wang, Y., Chen, Q., Liu, Z., Xiao, S., Wang, B., & Shi, B. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8816 · Cited by 43
“Clinical information, somatic mutation and gene expression data of patients with pancreatic cancer were obtained from two previously published cancer genome studies (11,12).”
InfluentialTargeting dendritic cells in pancreatic ductal adenocarcinoma
Deicher, A., Andersson, R. E., Tingstedt, B., Lindell, G., Bauden, M. P., & Ansari, D. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0585-0 · Cited by 38
“Recent molecular mapping has revealed an immunogenic subtype of pancreatic cancer that may be targetable through immune treatment [6].”
Emerging Roles of Fibroblast Growth Factor 10 in Cancer
Clayton, N. S., & Grose, R. P. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00499 · Cited by 39
“Expression of FGFR2 and FGFR1 are upregulated in approximately 25% of pancreatic adenocarcinoma (PDAC) cases and elevated stromal FGF10 expression coupled with high cancer cell FGFR2b expression has been correlated with poor prognosis (Cerami et al., 2012; Gao et al., 2013; Bailey et al., 2016).”
BackgroundDual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma
Hirotsu, Y., Otake, S., Ohyama, H., Amemiya, K., Higuchi, R., Oyama, T., Mochizuki, H., Goto, T., & Omata, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60361-3 · Cited by 42
High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1
Steins, A., van Mackelenbergh, M. G., van der Zalm, A. P., Klaassen, R., Serrels, B., Goris, S. G., Kocher, H. M., Waasdorp, C., de Jong, J. H., Tekin, C., et al. (2020) · EMBO reports · doi:10.15252/embr.201948780 · Cited by 39
“Mesenchymal-like PDAC features relatively poorly differentiated tumors (high-grade; G3), whereas non-mesenchymal subtypes feature relatively well-differentiated (low-grade; G1) tumors [16,17,19,20].”
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
Pompella, L., Tirino, G., Pappalardo, A., Caterino, M., Ventriglia, A., Nacca, V., Orditura, M., Ciardiello, F., & Vita, F. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082814 · Cited by 43
“Of note, the analysis of human and murine PDAC cell lines with “62-gene PDAssigner” was not able to identify even a single exocrine like cell line: Therefore, this subtype is probably an artifact from adjacent normal pancreas contaminating samples, as Moffitt [13] and Puleo [15] will show later.”
BackgroundInfluentialPerkail, S., Andricovich, J., Yan, K., & Tzatsos, A. (2020) · Nature Communications · doi:10.1038/s41467-020-16589-8 · Cited by 46
Carotenuto, P., Amato, F., Lampis, A., Rae, C. J., Hedayat, S., Previdi, M. C., Zito, D., Raj, M., Guzzardo, V., Sclafani, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27099-6 · Cited by 42
Self-citationB cells in pancreatic cancer stroma
Delvecchio, F. R., Goulart, M. R., Fincham, R. E. A., Bombadieri, M., & Kocher, H. M. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i11.1088 · Cited by 46
A biomimetic tumor model of heterogeneous invasion in pancreatic ductal adenocarcinoma
Bradney, M. J., Venis, S. M., Yang, Y., Konieczny, S. F., & Han, B. (2020) · Small · doi:10.1002/smll.201905500 · Cited by 38
The biological role of metabolic reprogramming in pancreatic cancer
Suzuki, T., Otsuka, M., Seimiya, T., Iwata, T., Kishikawa, T., & Koike, K. (2020) · MedComm · doi:10.1002/mco2.37 · Cited by 39
Andersen, H. B., Ialchina, R., Pedersen, S. F., & Czaplińska, D. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10004-4 · Cited by 50
Rodríguez, E., Boelaars, K., Brown, K., Madunić, K., van Ee, T., Dijk, F., Verheij, J., Li, R. J. E., Schetters, S. T. T., Meijer, L. L., et al. (2022) · Communications Biology · doi:10.1038/s42003-021-02934-0 · Cited by 46
Modeling Pancreatic Cancer with Patient-Derived Organoids Integrating Cancer-Associated Fibroblasts
Go, Y.-H., Choi, W. H., Bae, W. J., Jung, S., Cho, C., Lee, S. A., Park, J. S., Ahn, J. M., Kim, S. W., Lee, K. J., et al. (2022) · Cancers · doi:10.3390/cancers14092077 · Cited by 43
“Pancreatic adenocarcinoma is classified into several subtypes: basal and activated stromal types [10]; squamous, pancreatic progenitor, immunogenic, and aberrantly differentiated endocrine exocrine [11]; and four subtypes based on distinct phenotypes, including matrix- and immune-related signatures, α-smooth muscle ac…”
Backgroundde Andrés, M. P., Jackson, R., Felipe‐Abrio, I., Zagorac, S., Pilarsky, C. P., Schlitter, A. M., de Villarreal, J. M., Jang, G. H., Costello, E., Gallinger, S., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325803 · Cited by 40
Self-citationPancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies
Senturk, Z. N., Akdag, I., Deniz, B., & Sayi‐Yazgan, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152551 · Cited by 45
Kettle, J. G., Bagal, S. K., Barratt, D. G., Bodnarchuk, M. S., Boyd, S., Braybrooke, E. L., Breed, J., Cassar, D. J., Cosulich, S. C., Davies, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00746 · Cited by 40
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.